Research Grade Anti-Human GPRC5D (MCARH 109)

Catalog No.

DHK07703

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Human

Isotype

IgG

Clonality

Monoclonal

Target

GPRC5D, G-protein coupled receptor family C group 5 member D

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q9NZD1

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

MCARH-109, MCARH 109, MCARH109

Clone ID

MCARH 109

[Expression of GPRC5D in newly diagnosed patients with multiple myeloma detected by flow cytometry and its prognostic value]., PMID:40425453

Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review., PMID:40425184

SOHO State of the Art Updates and Next Questions | Manuscript Title: Bispecific T-Cell Engagers: Sequencing, B-Cell Maturation Antigen, GPRC5D, and Resistance., PMID:40382213

Bispecific Antibodies and CAR T in Multiple Myeloma: Appropriate Selection of Patients and Sequencing., PMID:40375902

Phase 1 study of talquetamab, a humanized GPRC5D x CD3 bispecific antibody, in Japanese patients with relapsed/refractory MM., PMID:40343678

A synthetic heavy chain variable domain antibody library (VHL) provides highly functional antibodies with favorable developability., PMID:40100169

Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study., PMID:40090350

Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody., PMID:39984633

The Evolving Landscape in Multiple Myeloma: From Risk Stratification to T Cell-Directed Advanced Therapies., PMID:39941892

Advancements in bispecific antibodies for multiple myeloma: What's new and what lies ahead., PMID:39880754

Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma., PMID:39778168

Novel Approaches of Cellular Therapy in Multiple Myeloma: Focus on Chimeric Antigen Receptor T-Cells., PMID:39733769

T cell margination: investigating the detour of T cells following forimtamig treatment in humanized mice., PMID:39686589

Anti-BCMA and GPRC5D bispecific antibodies in relapsed/refractory primary plasma cell leukemia: a case report., PMID:39676854

Comprehensive Review of Bispecific Antibody Constructs In Multiple Myeloma: Affinities, Dosing Strategies and Future Perspectives., PMID:39676006

Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy., PMID:39632797

Efficacy and Safety of Bispecific T-Cell Engagers in Relapsed/Refractory Multiple Myeloma: A Real-World Data-Based Case-Controlled Study., PMID:39608453

Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma., PMID:39476124

[Development and prospects of bispecific antibodies for multiple myeloma]., PMID:39358260

DNA vaccines against GPRC5D synergize with PD-1 blockade to treat multiple myeloma., PMID:39353958

Targeting GPRC5D for multiple myeloma therapy., PMID:39342286

A CD38/CD3xCD28 trispecific T-cell engager as a potentially active agent in multiple myeloma patients relapsed and/or refractory to anti-CD38 monoclonal antibodies., PMID:39308023

Evaluation of Drug-Drug Interaction Potential of Talquetamab, a T-Cell-Redirecting GPRC5D × CD3 Bispecific Antibody, as a Result of Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma in MonumenTAL-1, Using a Physiologically Based Pharmacokinetic Model., PMID:39285155

Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma., PMID:39271448

Bispecific antibodies in the treatment of multiple myeloma., PMID:39266530

Matching-adjusted indirect comparison of talquetamab vs selinexor-dexamethasone and vs belantamab mafodotin in patients with relapsed/refractory multiple myeloma., PMID:39226081

Targeting GPRC5D With Talquetamab: A New Frontier in Bispecific Antibody Therapy for Relapsed/Refractory Multiple Myeloma., PMID:39192558

T-cell redirecting bispecific antibody treatment in multiple myeloma: current knowledge and future strategies for sustained T-cell engagement., PMID:39185748

Structural Basis for the Recognition of GPRC5D by Talquetamab, a Bispecific Antibody for Multiple Myeloma., PMID:39181182

Real-world experience with clinical management of talquetamab in relapsed/refractory multiple myeloma: a qualitative study of US healthcare providers., PMID:39177290

Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma., PMID:39172759

Nursing Considerations for the Clinical Management of Adverse Events Associated with Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma., PMID:39155155

Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma., PMID:39145912

Fast and furious: Changing gears on the road to cure with chimeric antigen receptor T cells in multiple myeloma., PMID:39095225

Dermatological toxicities of talquetamab, a new bispecific antibody: case series and literature review., PMID:39094121

Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies., PMID:39033769

Bispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma., PMID:39001399

Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins., PMID:38961233

Bispecific Antibody Use in Patients With Lymphoma and Multiple Myeloma., PMID:38935881

The binding mechanism of an anti-multiple myeloma antibody to the human GPRC5D homodimer., PMID:38898050

B-cell maturation antigen-based therapies post-talquetamab in relapsed or refractory multiple myeloma., PMID:38895072

Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab., PMID:38871558

Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma., PMID:38802346

French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry., PMID:38747092

T-Cell Characteristics Impact Response and Resistance to T-Cell-Redirecting Bispecific Antibodies in Multiple Myeloma., PMID:38687588

Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives., PMID:38660139

Structure and function of therapeutic antibodies approved by the US FDA in 2023., PMID:38617189

Targeting GPRC5D in multiple myeloma., PMID:38607646

Peeling Back the Layers: Recurrent Talquetamab Skin Toxicity after Supportive Stem Cell Boost in Multiple Myeloma., PMID:38447541

Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study., PMID:38432433

Document Download

Research Grade Anti-Human GPRC5D (MCARH 109).pdf